Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 37037186)

  • 1. Effect of Food and a Proton-Pump Inhibitor on the Absorption of Encorafenib: An
    Piscitelli J; Hens B; Tomaszewska I; Wollenberg L; Litwiler K; McAllister M; Reddy M
    Mol Pharm; 2023 May; 20(5):2589-2599. PubMed ID: 37037186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of food and the proton pump inhibitor rabeprazole on the pharmacokinetics of GDC-0941 in healthy volunteers: bench to bedside investigation of pH-dependent solubility.
    Ware JA; Dalziel G; Jin JY; Pellett JD; Smelick GS; West DA; Salphati L; Ding X; Sutton R; Fridyland J; Dresser MJ; Morrisson G; Holden SN
    Mol Pharm; 2013 Nov; 10(11):4074-81. PubMed ID: 24099279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Physiologically Based Pharmacokinetic Modeling of Oral Absorption, pH, and Food Effect in Healthy Volunteers to Drive Alpelisib Formulation Selection.
    Gajewska M; Blumenstein L; Kourentas A; Mueller-Zsigmondy M; Lorenzo S; Sinn A; Velinova M; Heimbach T
    AAPS J; 2020 Oct; 22(6):134. PubMed ID: 33070288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the effects of formulation, food, or a proton-pump inhibitor on the pharmacokinetics of glasdegib (PF-04449913) in healthy volunteers: a randomized phase I study.
    Shaik N; Hee B; Wei H; LaBadie RR
    Cancer Chemother Pharmacol; 2019 Mar; 83(3):463-472. PubMed ID: 30536154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gastrointestinal dissolution, supersaturation and precipitation of the weak base indinavir in healthy volunteers.
    Rubbens J; Brouwers J; Tack J; Augustijns P
    Eur J Pharm Biopharm; 2016 Dec; 109():122-129. PubMed ID: 27693678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Negative Food Effect of Danirixin: Use of PBPK Modelling to Explore the Effect of Formulation and Meal Type on Clinical PK.
    Lloyd RS; Hingle MI; Bloomer JC; Charles SJ; Butler JM; Paul A; Zhu X; Miller B; D'Amico D; Donald A; Tal-Singer R; Ambery C
    Pharm Res; 2020 Oct; 37(12):233. PubMed ID: 33123802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of food or proton pump inhibitor treatment on the bioavailability of dacomitinib in healthy volunteers.
    Ruiz-Garcia A; Masters JC; Mendes da Costa L; LaBadie RR; Liang Y; Ni G; Ellery CA; Boutros T; Goldberg Z; Bello CL
    J Clin Pharmacol; 2016 Feb; 56(2):223-30. PubMed ID: 26179237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bioequivalence and Relative Bioavailability Studies to Assess a New Acalabrutinib Formulation That Enables Coadministration With Proton-Pump Inhibitors.
    Sharma S; Pepin X; Burri H; Zheng L; Kuptsova-Clarkson N; de Jong A; Yu T; MacArthur HL; Majewski M; Byrd JC; Furman RR; Ware JA; Mann J; Ramies D; Munugalavadla V; Sheridan L; Tomkinson H
    Clin Pharmacol Drug Dev; 2022 Nov; 11(11):1294-1307. PubMed ID: 36029150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of posaconazole and diltiazem on pharmacokinetics of encorafenib, a BRAF V600 kinase inhibitor for melanoma and colorectal cancer with BRAF mutations.
    Hahn E; Chavira R; Wollenberg L; Tan W; Reddy MB
    Clin Transl Sci; 2023 Dec; 16(12):2675-2686. PubMed ID: 37837178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Randomized, Crossover Study on the Effect of Food on the Pharmacokinetic Characteristics of Morphine ARER (MorphaBond™ ER), an Abuse-Deterrent Formulation of Extended-Release Morphine.
    Kinzler ER; Pantaleon C; Iverson M; Aigner S
    Adv Ther; 2019 Sep; 36(9):2394-2401. PubMed ID: 31278694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
    Chen C; Bujanover S; Kareht S; Rapoport AM
    Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biopharmaceutic
    Arora S; Pansari A; Kilford P; Jamei M; Gardner I; Turner DB
    Mol Pharm; 2020 Jul; 17(7):2329-2344. PubMed ID: 32427480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting pharmacokinetic food effects using biorelevant solubility media and physiologically based modelling.
    Jones HM; Parrott N; Ohlenbusch G; Lavé T
    Clin Pharmacokinet; 2006; 45(12):1213-26. PubMed ID: 17112297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of Gastrointestinal Simulator, Mass Transport Analysis, and Absorption Simulation to Investigate the Impact of pH Modifiers in Mitigating Weakly Basic Drugs' Performance Issues Related to Gastric pH: Palbociclib Case Study.
    Kuminek G; Salehi N; Waltz NM; Sperry DC; Greenwood DE; Hate SS; Amidon GE
    Mol Pharm; 2023 Jan; 20(1):147-158. PubMed ID: 36367432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In Vivo Dissolution and Systemic Absorption of Immediate Release Ibuprofen in Human Gastrointestinal Tract under Fed and Fasted Conditions.
    Koenigsknecht MJ; Baker JR; Wen B; Frances A; Zhang H; Yu A; Zhao T; Tsume Y; Pai MP; Bleske BE; Zhang X; Lionberger R; Lee A; Amidon GL; Hasler WL; Sun D
    Mol Pharm; 2017 Dec; 14(12):4295-4304. PubMed ID: 28937221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of food on the pharmacokinetics of oxycodone and naltrexone from ALO-02, an extended release formulation of oxycodone with sequestered naltrexone.
    Gandelman K; Lamson M; Salageanu J; Bramson C; Matschke K; Malhotra B
    Clin Pharmacol Drug Dev; 2015 Sep; 4(5):370-6. PubMed ID: 27137146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive clinical pharmacology characterization of AZD4635 in healthy participants to support dosing considerations.
    Moorthy G; Pouliot GP; Graham L; Pilling E; Jung L; Alcobi R; Zhu Y; Li Y; Sidhu S; Forte P; Mugundu G
    Br J Clin Pharmacol; 2023 Sep; 89(9):2775-2787. PubMed ID: 37055936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanistic understanding of the effect of PPIs and acidic carbonated beverages on the oral absorption of itraconazole based on absorption modeling with appropriate in vitro data.
    Fotaki N; Klein S
    Mol Pharm; 2013 Nov; 10(11):4016-23. PubMed ID: 23947755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 1 Study Evaluating the Effects of the Proton Pump Inhibitor Rabeprazole and Food on the Pharmacokinetics of Lorlatinib in Healthy Participants.
    Xu H; O'Gorman MT; Nepal S; James LP; Ginman K; Pithavala YK
    Clin Pharmacol Drug Dev; 2021 Nov; 10(11):1395-1404. PubMed ID: 34288547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of food intake on the pharmacokinetic properties of mirabegron oral controlled-absorption system: a single-dose, randomized, crossover study in healthy adults.
    Lee J; Zhang W; Moy S; Kowalski D; Kerbusch V; van Gelderen M; Sawamoto T; Grunenberg N; Keirns J
    Clin Ther; 2013 Mar; 35(3):333-41. PubMed ID: 23497763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.